BioCentury | Dec 23, 2020
Deals

Insilico caps year of deals by opening its computational platforms to pharmas’ in-house teams

...well honed to identify senolytic targets, which were the focus of the company’s deal with Taisho...
BioCentury | Oct 10, 2017
Distillery Therapeutics

Neurology

...testing NF-κB inhibitors in SCA17 models. Toyama Chemical Co. Ltd. , Eisai Co. Ltd. and Taisho...
BioCentury | Aug 8, 2016
Clinical News

Zosyn tazobactam/piperacillin regulatory update

...a JV between Taisho and Toyama, markets Zosyn. Taiho Pharmaceutical Co. Ltd. , Tokyo, Japan Taisho...
BioCentury | May 2, 2016
Company News

Chugai, Taisho Pharmaceutical Holdings, Roche sales and marketing update

...Chugai and Taisho launched a monthly oral formulation of Boniva ibandronate in Japan to treat osteoporosis...
...of a 100 mg tablet, the recommended monthly dose, is Y2,790 ($25.11). Chugai partnered with Taisho...
...owned by Roche (see BioCentury, Sept. 18, 2006). Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Taisho...
BioCentury | Feb 8, 2016
Company News

Taisho Pharmaceutical Holdings, Teijin sales and marketing update

...transdermal NSAID patch containing S-flurbiprofen and mentha oil from Taisho under a March 2015 deal. Taisho...
BioCentury | Feb 1, 2016
Clinical News

Boniva ibandronate regulatory update

...Chugai and Taisho said Japan approved a monthly oral formulation of Boniva ibandronate to treat osteoporosis...
...treat osteoporosis. Japan approved a monthly IV formulation of Boniva in 2013. Chugai partnered with Taisho...
...oral formulation to prevent osteoporosis in postmenopausal women. Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Taisho...
BioCentury | Dec 14, 2015
Strategy

Networking in Japan

...2009, the JV paid an undisclosed sum to acquire a majority stake in generics play Taisho...
...and Welfare (MHLW), Tokyo, Japan Pharmaceutical Research and Manufacturers of America (PhRMA) , Washington, D.C. Taisho...
BioCentury | Dec 7, 2015
Clinical News

Careram regulatory update

...Toyama co-developed Careram/Kolbet in Japan. Eisai and Taisho Toyama Pharmaceutical Co. Ltd., a JV between Taisho...
...a subsidiary of Fujifilm Holdings Corp. (Tokyo:4901, Tokyo, Japan). Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Taisho...
BioCentury | Oct 8, 2015
Product R&D

Medicines Co.'s double play

...Inc. (NYSE:PFE) Sulbactam Ampicillin Unasyn Bacterial infections Toyama Chemical Co. Ltd.; Taiho Pharmaceutical Co. Ltd.; Taisho...
BioCentury | Aug 3, 2015
Company News

Ablynx, Taisho deal

...Ablynx granted Taisho exclusive, Japanese rights to develop and commercialize ozoralizumab to treat rheumatoid arthritis. Ablynx...
...million up front and is eligible to receive undisclosed development and commercial milestones and royalties. Taisho...
...is a Nanobody against tumor necrosis factor (TNF) alpha . Ablynx N.V. (Euronext:ABLX), Ghent, Belgium Taisho Pharmaceutical Co. Ltd....
Items per page:
1 - 10 of 123
BioCentury | Dec 23, 2020
Deals

Insilico caps year of deals by opening its computational platforms to pharmas’ in-house teams

...well honed to identify senolytic targets, which were the focus of the company’s deal with Taisho...
BioCentury | Oct 10, 2017
Distillery Therapeutics

Neurology

...testing NF-κB inhibitors in SCA17 models. Toyama Chemical Co. Ltd. , Eisai Co. Ltd. and Taisho...
BioCentury | Aug 8, 2016
Clinical News

Zosyn tazobactam/piperacillin regulatory update

...a JV between Taisho and Toyama, markets Zosyn. Taiho Pharmaceutical Co. Ltd. , Tokyo, Japan Taisho...
BioCentury | May 2, 2016
Company News

Chugai, Taisho Pharmaceutical Holdings, Roche sales and marketing update

...Chugai and Taisho launched a monthly oral formulation of Boniva ibandronate in Japan to treat osteoporosis...
...of a 100 mg tablet, the recommended monthly dose, is Y2,790 ($25.11). Chugai partnered with Taisho...
...owned by Roche (see BioCentury, Sept. 18, 2006). Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Taisho...
BioCentury | Feb 8, 2016
Company News

Taisho Pharmaceutical Holdings, Teijin sales and marketing update

...transdermal NSAID patch containing S-flurbiprofen and mentha oil from Taisho under a March 2015 deal. Taisho...
BioCentury | Feb 1, 2016
Clinical News

Boniva ibandronate regulatory update

...Chugai and Taisho said Japan approved a monthly oral formulation of Boniva ibandronate to treat osteoporosis...
...treat osteoporosis. Japan approved a monthly IV formulation of Boniva in 2013. Chugai partnered with Taisho...
...oral formulation to prevent osteoporosis in postmenopausal women. Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Taisho...
BioCentury | Dec 14, 2015
Strategy

Networking in Japan

...2009, the JV paid an undisclosed sum to acquire a majority stake in generics play Taisho...
...and Welfare (MHLW), Tokyo, Japan Pharmaceutical Research and Manufacturers of America (PhRMA) , Washington, D.C. Taisho...
BioCentury | Dec 7, 2015
Clinical News

Careram regulatory update

...Toyama co-developed Careram/Kolbet in Japan. Eisai and Taisho Toyama Pharmaceutical Co. Ltd., a JV between Taisho...
...a subsidiary of Fujifilm Holdings Corp. (Tokyo:4901, Tokyo, Japan). Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Taisho...
BioCentury | Oct 8, 2015
Product R&D

Medicines Co.'s double play

...Inc. (NYSE:PFE) Sulbactam Ampicillin Unasyn Bacterial infections Toyama Chemical Co. Ltd.; Taiho Pharmaceutical Co. Ltd.; Taisho...
BioCentury | Aug 3, 2015
Company News

Ablynx, Taisho deal

...Ablynx granted Taisho exclusive, Japanese rights to develop and commercialize ozoralizumab to treat rheumatoid arthritis. Ablynx...
...million up front and is eligible to receive undisclosed development and commercial milestones and royalties. Taisho...
...is a Nanobody against tumor necrosis factor (TNF) alpha . Ablynx N.V. (Euronext:ABLX), Ghent, Belgium Taisho Pharmaceutical Co. Ltd....
Items per page:
1 - 10 of 123